A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Conditions
- Early Breast Cancer
- Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
Interventions
- DRUG: Atirmociclib
- DRUG: giredestrant
- OTHER: Atirmociclib placebo
Sponsor
Pfizer